Deerfield commits up to $130 million over 10 years to fund translational research at Dana-Farber
Dana-Farber Cancer Institute and Deerfield Management Company, a healthcare investment management firm focused on advancing healthcare through investment, information and philanthropy, have formed a major translational research partnership to accelerate the development of therapeutics and diagnostics for cancer. Deerfield has committed up to $130 million over the next 10 years to advance research at Dana-Farber and translate scientific discoveries with potential applications for patients.
Riverway Discoveries represents the first time Deerfield has created a second such partnership with one of its academic collaborators. In the first agreement, announced in 2018, Deerfield committed $80 million to create the Center for Protein Degradation at Dana-Farber.
DLA Piper advises Pairwise in US$90 million Series B financing
News provided by
Share this article
Share this article
NEW YORK, Feb. 5, 2021 /PRNewswire/ DLA Piper represented food technology company Pairwise in its recent US$90 Series B financing. The round was led by Pontifax Global Food and Agriculture Technology Fund and existing investor Deerfield Management Company, and included new investor Temasek and existing investor Leaps by Bayer.
Pairwise is using cutting-edge technology to build a healthier world by introducing better fruits and vegetables with improved taste, enhanced convenience, increased shelf life, improved yield, simplified harvesting or lengthened season availability. To address challenges with inconsistent flavor, seeds, shelf life, year-round availability and snackability, Pairwise will bring to the produce aisle new varieties of nutritious fruits and vegetables, and is currently developing new types of leafy greens, berries and cherries. Its first prod
Pairwise, an agricultural biotechnology company that applies gene-editing techniques to food crops, has raised $90 million in funding as it eyes commercialization of its first product next year.
The Series B round of funding was led by Pontifax Global Food and Agriculture Technology Fund and Deerfield Management Company, an earlier investor in the startup.
“Our investment in Pairwise reflects our thematic focus on the convergence of biotechnology and agriculture and the use of CRISPR technology to improve health and nutrition in food and agriculture,” Pontifax AgTech co-founder and managing partner Ben Belldegrun said in a prepared statement. “We believe that the combination of Pairwise’s gene editing platform, plant breeding expertise, and consumer food understanding creates a powerful engine that will be a game changer.”
Pairwise, a company that is developing new types of leafy greens, berries, and cherries, announced the closing
of its $90 million Series B funding round, signaling a new frontier in healthy, sustainable food innovation. Funding for the round was led by Pontifax Global Food and Agriculture Technology Fund (Pontifax AgTech), a pioneering growth capital investor in food and agriculture technology, and existing investor Deerfield Management Company (Deerfield), an investment firm dedicated to advancing healthcare through investment, information and philanthropy. Also joining the Series B round are new investor Temasek, an investment company headquartered in Singapore, and existing investor Leaps by Bayer, which invests in paradigm-shifting advances in the life sciences sector, including agriculture and health.
DURHAM Pairwise has closed its $90 million Series B funding round backing its tech for sustainable food innovation.
Pairwise has built a unique crop trait development platform, based on CRISPR gene-editing technology licensed from leading research organizations, including Massachusetts General Hospital (MGH) and the Broad Institute of MIT and Harvard (Broad Institute).
Funding for the round was led by Pontifax Global Food and Agriculture Technology Fund (Pontifax AgTech), a pioneering growth capital investor in food and agriculture technology, and existing investor Deerfield Management Company (Deerfield), an investment firm dedicated to advancing healthcare through investment, information and philanthropy.
Also joining the Series B round are new investor Temasek, an investment company headquartered in Singapore, and existing investor Leaps by Bayer, which invests in paradigm-shifting advances in the life sciences sector, including agriculture and health.